Health Canada's Action Plan For Non-prescription Drugs

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
As part of Health Canada's initiative to update its approach to regulating self-care products, including non-prescription drugs (broadly, also including cosmetics and natural health products)...
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

As part of Health Canada's initiative to update its approach to regulating self-care products, including non-prescription drugs (broadly, also including cosmetics and natural health products), and as a first step in advance of a regulatory proposal to simplify market access for non-prescription drug products, Health Canada has developed a Non-prescription Drug Action Plan.

The action plan introduces policy and operational solutions to remove barriers for getting non-prescription drugs (excluding ethical drugs, controlled substances, and biocides) to market, by removing repetitious and onerous requirements and introducing flexibilities for industry.

Short-term solutions were announced and effective December 2022, with updates relating to optional subheadings for the Canadian Drug Facts Table, product monograph and patient medication information leaflets, and label mock-up requirements. Medium- and long-term solutions are targeted for the end of 2023 and the end of 2024; Health Canada will publish further information once the work is completed, for example by way of notices.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More